Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast

Forecasting

Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

RNC Pharma Database Update: Pharmaceutical Drug Production in Russia (November 2018)

Wednesday, December 26, 2018

Between January and November 2018, Russia produced 305.1 bln RUB worth of pharmaceutical drugs (dispatch prices, VAT included), which is in monetary terms 1.1% higher than that of the same period of 2017. In physical terms, the dynamics are -5.6%, with 3.85 bln units.

The dynamics for the period in physical terms are negative for both OTC and Rx production, -5.4% and 5.9%, respectively. In November, the dynamics for OTC drug production were -4.3%, while those for Rx drug production were +1.7%. If calculated in minimum dosage units (MDU), the dynamics are +0.4%.

Among the top 10 EphMRA second level groups with the biggest production volumes in physical terms, systemic antibiotics still have the lowest dynamics (-26%.) That is the result of the epidemiological situation as the ARVI and flu frequency has dropped by 2.6% and 25% since January, respectively. Out of the top pharmaceuticals, only the production of Kagocel by Nearmedic Plus has shown positive dynamics. The productions of painkillers and anti-cold and flu pharmaceutical drugs have also decreased, -19% and 10%, respectively. Among the top pharmaceuticals, the production of nose medicines has the best dynamics, +15%. Armavirskaya Biofabrika has increased its production, in particular of Naphtyzin (by 94 times.)

As for Rx pharmaceutical drugs, the productions of solutions for intravenous injections and systemic antibiotics have the lowest dynamics, -27% and 23%, respectively. The production of beta-adrenoblockers has the highest dynamics, +61%. Besides Merck Group, which has localized the production of its Concor at the facilities of Russian Nanolek, here we have Izvarino Pharma and Avexima, both of which actively produce Bisoprolol.

Read more about pharmaceutical drug production in Russia (October results) here: http://rncph.com/news/06_12_2018

Dynamics of pharmaceutical drug production in Russia, including production of pharmaceuticals of foreign companies on owned or contract plants, in physical (units) and monetary terms (RUB, VAT included) (January 2017 – November 2018)

Share: